Listing 3 - Actual negotiations

Indication:

In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.

Indication:

To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.

Indication:

Neuromyelitis optica spectrum disorder (NMOSD)

Indication:

Polyneuropathy in hereditary transthyretin-mediated amyloidosis

Indication:

Hidradenitis Suppurativa

Indication:

Ulcerative Colitis

Indication:

Adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Indication:

For the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.

Indication:

Ulcerative Colitis and Crohn's Disease

Indication:

As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen